Myasthenia gravis following alemtuzumab therapy for multiple sclerosis.
作者信息
Midaglia Luciana, Gratacòs Margarida, Caronna Edoardo, Raguer Nuria, Sastre-Garriga Jaume, Montalban Xavier, Tintoré Mar
机构信息
From the Servei de Neurologia/Neuroimmunologia, Multiple Sclerosis Centre of Catalonia (CEM-Cat) (L.M., J.S.-G., X.M., M.T.), Servei de Neurofisiologia Clínica, Unitat d'Electromiografia (M.G., N.R.), and Servei de Neurologia (E.C.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; and Division of Neurology (X.M.), University of Toronto, St Michael's Hospital, Canada.
出版信息
Neurology. 2018 Sep 25;91(13):622-624. doi: 10.1212/WNL.0000000000006251. Epub 2018 Aug 24.
Abstract
摘要
相似文献
1
Myasthenia gravis following alemtuzumab therapy for multiple sclerosis.阿仑单抗治疗多发性硬化症后发生的重症肌无力。
Neurology. 2018 Sep 25;91(13):622-624. doi: 10.1212/WNL.0000000000006251. Epub 2018 Aug 24.
2
Autoimmune encephalitis following alemtuzumab treatment of multiple sclerosis.多发性硬化症用阿仑单抗治疗后出现自身免疫性脑炎。
Mult Scler Relat Disord. 2019 Feb;28:31-33. doi: 10.1016/j.msard.2018.12.004. Epub 2018 Dec 3.
3
Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis.与阿仑单抗输注相关的急性冠状动脉综合征在多发性硬化症中的情况
Neurology. 2018 May 1;90(18):852-854. doi: 10.1212/WNL.0000000000005417. Epub 2018 Mar 30.
4
[Coexistence of multiple sclerosis and myasthenia gravis].
Neurol Neurochir Pol. 1991 Mar-Apr;25(2):259-62.
5
Recurrent and universal alopecia areata following alemtuzumab treatment in multiple sclerosis: A secondary autoimmune disease.阿仑单抗治疗多发性硬化症后出现复发性和普遍性斑秃：一种继发性自身免疫性疾病。
Mult Scler Relat Disord. 2019 Jan;27:406-408. doi: 10.1016/j.msard.2018.12.005. Epub 2018 Dec 3.
6
Myasthenia gravis and multiple sclerosis: an uncommon presentation.重症肌无力与多发性硬化症：一种不常见的表现。
Arq Neuropsiquiatr. 2008 Jun;66(2A):251-3. doi: 10.1590/s0004-282x2008000200023.
7
[Multiple sclerosis associated with myasthenia gravis].[多发性硬化症合并重症肌无力]
Sov Med. 1990(7):110-1.
8
Co-occurrence of multiple sclerosis and myasthenia gravis: A case report and review of immunological theories.多发性硬化症和重症肌无力的同时发生：病例报告及免疫理论综述。
Mult Scler Relat Disord. 2019 Sep;34:135-136. doi: 10.1016/j.msard.2019.06.027. Epub 2019 Jun 26.
9
Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment.显著但罕见：阿仑单抗治疗多发性硬化症后出现中性粒细胞减少症。
Mult Scler Relat Disord. 2017 Nov;18:181-183. doi: 10.1016/j.msard.2017.09.028. Epub 2017 Sep 25.
10
[Evaluation of 4 cases with clinical characteristics of myasthenia gravis and multiple sclerosis].[4例具有重症肌无力和多发性硬化临床特征病例的评估]
Rinsho Shinkeigaku. 1975 Nov;15(11):888-94.
引用本文的文献
1
Development of a novel tool for individual treatment trials in mucopolysaccharidosis.一种用于黏多糖贮积症个体治疗试验的新型工具的研发。
J Inherit Metab Dis. 2025 Jan;48(1):e12816. doi: 10.1002/jimd.12816. Epub 2024 Nov 21.
2
An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis.一种用于黏多糖贮积症循证、个性化治疗试验的创新工具。
Pharmaceutics. 2023 May 22;15(5):1565. doi: 10.3390/pharmaceutics15051565.
3
Cross-syndrome: myasthenia gravis and the demyelinating diseases of the central nervous system combination. Systematic literature review and case reports.交叉综合征：重症肌无力与中枢神经系统脱髓鞘疾病合并症。系统文献综述及病例报告。
Acta Neurol Belg. 2023 Apr;123(2):367-374. doi: 10.1007/s13760-022-01926-z. Epub 2022 Jun 14.
4
Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic Management.自身免疫性神经肌肉接头疾病中的抗体治疗：肌无力危象和慢性管理的方法。
Neurotherapeutics. 2022 Apr;19(3):897-910. doi: 10.1007/s13311-022-01181-3. Epub 2022 Feb 14.
5
Drugs That Induce or Cause Deterioration of Myasthenia Gravis: An Update.诱发或导致重症肌无力病情恶化的药物：最新进展
J Clin Med. 2021 Apr 6;10(7):1537. doi: 10.3390/jcm10071537.
6
Clinical characteristics of autoimmune disorders in the central nervous system associated with myasthenia gravis.与重症肌无力相关的中枢神经系统自身免疫性疾病的临床特征。
J Neurol. 2019 Nov;266(11):2743-2751. doi: 10.1007/s00415-019-09461-3. Epub 2019 Jul 24.
本文引用的文献
1
Acquired haemophilia A complicating alemtuzumab therapy for multiple sclerosis.获得性血友病A并发阿仑单抗治疗多发性硬化症。
BMJ Case Rep. 2017 Dec 5;2017:bcr-2017-223016. doi: 10.1136/bcr-2017-223016.
2
Alopecia Universalis following Alemtuzumab Treatment in Multiple Sclerosis: A Barely Recognized Manifestation of Secondary Autoimmunity-Report of a Case and Review of the Literature.阿仑单抗治疗多发性硬化后出现全秃：继发性自身免疫的一种罕见表现——1例报告及文献复习
Front Neurol. 2017 Oct 30;8:569. doi: 10.3389/fneur.2017.00569. eCollection 2017.
3
Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.阿仑单抗治疗复发型多发性硬化症（CARE-MS II）5年随访：疗效与安全性结果
Neurology. 2017 Sep 12;89(11):1117-1126. doi: 10.1212/WNL.0000000000004354. Epub 2017 Aug 23.
4
A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis.一篇系统性综述：多发性硬化症中的自身免疫性疾病的发病率和流行率。
Mult Scler. 2015 Mar;21(3):282-93. doi: 10.1177/1352458514564490. Epub 2014 Dec 22.
5
First reported case of diabetes mellitus type 1 as a possible secondary autoimmune disease following alemtuzumab treatment in MS.首例1型糖尿病可能是阿仑单抗治疗多发性硬化症后的继发性自身免疫性疾病。
J Neurol. 2014 Oct;261(10):2016-8. doi: 10.1007/s00415-014-7448-y. Epub 2014 Aug 1.
6
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.阿仑单抗治疗缓解复发型多发性硬化症患者：一项疾病修饰治疗后随机对照 3 期试验。
Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1.
7
Myasthenia gravis and multiple sclerosis: an uncommon presentation.重症肌无力与多发性硬化症：一种不常见的表现。
Arq Neuropsiquiatr. 2008 Jun;66(2A):251-3. doi: 10.1590/s0004-282x2008000200023.
8
Development of myasthenia gravis in two patients with multiple sclerosis following interferon beta treatment.两名多发性硬化症患者在接受β-干扰素治疗后发生重症肌无力。
J Neurol Neurosurg Psychiatry. 2004 Jul;75(7):1079. doi: 10.1136/jnnp.2003.028233.
9
Development of myasthenia gravis in a patient with multiple sclerosis during treatment with glatiramer acetate.一名多发性硬化症患者在接受醋酸格拉替雷治疗期间发生重症肌无力。
J Neurol. 2000 Sep;247(9):713. doi: 10.1007/s004150070118.
Zotero 插件